Headlines Covid-19 Specialties Trending Feeds Videos

The Lancet Rheumatology - In line with previously published data, incidences of all-cause mortality and AESIs were similar in patients given belimumab and placebo, except for serious infusion...

COVID-19 vasculitis and novel vasculitis mimics

posted 2 weeks

Mashup Score: 4

The Lancet Rheumatology - COVID-19 has been occasionally linked to histologically confirmed cutaneous vasculitis and a Kawasaki-like vasculitis, with these entities generally having minimal or no lung involvement...

Divergent effects of acute versus chronic glucocorticoids in COVID-19

posted 6 days

Mashup Score: 3

The Lancet Rheumatology - The COVID-19 pandemic has precipitated a search for both effective treatments and patient factors that predict poor outcome. Although agents ranging from convalescent plasma...

Systemic lupus erythematosus: diverting progress to chase rare side effects?

posted 1 month

Mashup Score: 2

The Lancet Rheumatology - In The Lancet Rheumatology, Saira Sheikh and colleagues report results of the BASE trial,1 a phase 4 randomised control trial designed to assess mortality...

Is chronic non-infectious osteomyelitis with mandibular involvement a distinct disease?

posted 1 week

Mashup Score: 2

The Lancet Rheumatology - Chronic non-infectious osteomyelitis is an autoinflammatory bone disorder that can affect patients’ quality of life and psychosocial development.1,2 The disease shows substantial variation in...

The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis

posted 1 month

Mashup Score: 2

The Lancet Rheumatology - Cardiopulmonary complications are a leading cause of death in systemic sclerosis. Pulmonary hypertension in particular carries a high mortality and morbidity burden. Patients with...

COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study

posted 2 weeks

Mashup Score: 1

The Lancet Rheumatology - The ongoing COVID-19 pandemic caused by the novel β-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a serious challenge for the management of...

The Lancet Rheumatology - We found no evidence for efficacy of sirolimus for treating inclusion body myositis based on maximal voluntary isometric knee extension strength and other muscle...

  • 44 pts of Inclusion body myositis were randomized to either PBO or sirolimus 2 mg/d. At 12 mos there were no signif differences betw groups for motor strength , but sirolimus had more SAEs (45 vs 27%); yet sirolimus had better HAQ, FVC & 6-min walk times. https://t.co/YhnRTnaGFl

Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study

posted 1 month

Mashup Score: 1

The Lancet Rheumatology - The risks of severe COVID-19 outcomes have improved over time in patients with rheumatic and musculoskeletal disease but remain substantial. These findings might reflect...

The Lancet Rheumatology - PF-06826647 showed significant improvement in disease activity within 4 weeks of dosing with an acceptable safety profile. PF-06826647 holds promise over conventional oral treatments...